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Abstract
Background: In hemodialysis, extracorporeal blood flow (Qb) recommendation is 300–500 mL/
min. To achieve the best Qb, we based our prescription on dynamic arterial line pressure (DALP).
Methods:  This prospective study included 72 patients with catheter Group 1 (G1), 1877
treatments and 35 arterio-venous (AV) fistulae Group 2 (G2), 1868 treatments. The dialysis staff
was trained to prescribe Qb sufficient to obtain DALP between -200 to -250 mmHg. We measured
ionic clearance (IK: mL/min), access recirculation, DALP (mmHg) and Qb (mL/min). Six
prescription zones were identified: from an optimal A zone (Qb > 400, DALP -200 to -250) to
zones with lower Qb E (Qb < 300, DALP -200 to -250) and F (Qb < 300, DALP > -199).
Results: Treatments distribution in A was 695 (37%) in G1 vs. 704 (37.7%) in G2 (P = 0.7). In B
150 (8%) in G1 vs. 458 (24.5%) in G2 (P < 0.0001). Recirculation in A was 10.0% (Inter quartile rank,
IQR 6.5, 14.2) in G1 vs. 9.8% (IQR 7.5, 14.1) in G2 (P = 0.62). IK in A was 214 ± 34 (G1) vs. 213 ±
35 (G2) (P = 0.65). IK Anova between G2 zones was: A vs. C and D (P < 0.000001). Staff
prescription adherence was 81.3% (G1) vs. 84.1% (G2) (P = 0.02).
Conclusion: In conclusion, an optimal Qb can de prescribed with DALP of -200 mmHg. Staff
adherence to DLAP treatment prescription could be reached up to 81.3% in catheters and 84.1%
in AV fistulae.
Background
In dialysis, the clearance directly depends on solute char-
acteristics (small and middle molecular weight), mem-
brane properties (surface area, thickness, efficiency),
dialysate flow, and extracorporeal blood flow (Qb) [1,2].
The later is operator dependent, but after selecting the
membrane and the dialysate flow rate, Qb prescription is
the greatest factor that can be optimized to obtain a
greater solute clearance. The Kidney Disease Outcome
Quality Initiative (K/DOQI) vascular access recommenda-
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tions for Qb are between 300 to 500 mL/min [3-5]. This
flow is obtained with a peristaltic pump. The pressure gen-
erated by the pump carries blood flow into the arterial seg-
ment of the dialysis circuit (arterial line) and is measured
continuously, denominated dynamic arterial line pressure
(DALP). DALP is a negative pressure that has been used to
determine catheter dysfunction, which is identified when
a dialysis blood flow of 300 mL/min is not being attained
in a catheter previously able to deliver greater Qb than
350 mL/min and at a pre pump pressure of -250 mmHg3.
The instrumentation and continuous measurement of the
pressures in the arterial and venous lines allow us to know
static and dynamic parameters of the internal pressure in
the access site. Pressure measurements have been utilized
in the diagnoses of stenosis in the venous side of the
access (dynamic and static venous pressure or intra-access
pressure), stenosis in the arterial side of the access (static
arterial intra-access pressure) or stenosis intra-access (Dif-
ference between arterial static pressure and venous static
pressure) [6,7]. The study of dynamic venous pressure has
demonstrated its usefulness in stenosis detection and
thrombosis prevention in grafts [8-13]. Nevertheless these
techniques have poor predictive value because the effec-
tiveness to use a ratio of the venous static normalized
pressure to the mean arterial pressure in an arterio-venous
(AV) graft depends on multiple factors, such as graft loca-
tion, vascular size, needle location, differentiating
between averaged pressures and central pressures. Neither
static venous pressure nor dynamic venous pressure has
exhibited satisfactory sensitivity or specificity for graft
thrombosis [14]. Very little information exists about
dynamic arterial line pressure with the exception of its
utility in diagnosis of catheter failure. Yet dynamic arterial
line pressure can be used for monitoring and optimiza-
tion of dialysis Qb. K/DOQI research recommendations3
proposed investigations to define the optimum value of
Qb, because the range between 300 to 500 ml/min is
wide, and an additional need is to reexamine the defini-
tion of catheter dysfunction and expand the definition
beyond blood flow rates [15]. We propose that the indi-
vidual prescription of dialysis blood flow, within this
wide range of Qb can be optimized for each vascular
access based on DALP.
Methods
Patients
We enrolled 91 patients from our chronic hemodiafiltra-
tion (HDF) dialysis unit and in the renal transplant pro-
gram from our institute, who received 3 HDF sessions per
week (11.5 to 12 hrs/wk). According with their type of
vascular access, we divided the study population in two
groups: jugular posterior dual-lumen catheters (Group 1)
and arterial venous (AV) internal fistulae (Group 2). The
dialysis staff was trained to prescribe a Qb enough to
obtain a DALP between -200 to -250 mmHg to a maxi-
mum Qb goal of 500 ml/min. Patients received anticoag-
ulation with heparin sodium 2.000 units at the beginning
of treatment and 1000 units per hour. Additionally, the
system filters and lines were heparinised with 1000 units
in a dilution of 1 liter of 0.9% saline solution. Institu-
tional policies for patients who are prepared for living
donor kidney transplantation undergo dialysis catheters.
Patients were dialyzed for only a limited time period (1 to
3 months) as they were waiting for living related kidney
transplantation. The hospital usually does not provide
tunneled catheters. Patients on the waiting list for cadav-
eric donors are made arterio venous fistula. The unit of the
Institute of Cardiology Ignacio Chavez has just hemodia-
filtration machines.
Treatments
Postdilutional HDF sessions were delivered by volumetric
dialysis machines (4008 H; Fresenius Medical Care
[FMC], Bad Homburg, Germany). The HDF volume was
17.64 ± 4.9 liters. The machines are equipped with a pre
pump measuring system for dynamic arterial line pres-
sure, a blood temperature monitor (BTM) (FMC, Bad
Homburg, Germany) for measurements of access recircu-
lation, and an on-line clearance monitor (OCM) (FMC,
Bad Homburg, Germany). Polysulfone membrane dialyz-
ers F-60 and F-80 were used (FMC. Walnut Creek, CA).
The material of the blood pump segment of the blood line
was transparent latex-free rubber for medical use (Fresen-
ius M.C., Fresenius Medical Care AG & Co. KGaA, Bad
Homburg, Germany).
Dialysis filters and blood lines were re-used up to 10 ± 4
times and disinfected by formaldehyde after each treat-
ment. Ultra pure bicarbonate dialyzate was delivered. The
institutional research committee approved the study.
Group 1 had 12-French dual-lumen catheters (Niagara®,
BARD, Utah, USA). The placement of the catheter was jug-
ular posterior and was performed by the physician of the
third year of postgraduate nephrology; the measures were
taken for a period of 12 months. In Group 2 we included
19 permanent vascular access points, with native arteriov-
enous fistulas that were at least 12 weeks old. The ana-
tomic location of the fistulas was, in the lower left arm
14%, in the upper left arm 43%, in the upper left arm 43%
and in the upper right arm 43%. This group used 14-
French internal diameter needles. Besides the policy of
our center, the patients had neither fluid and salt nor die-
tary restrictions. A high protein and calorie intake (protein
catabolic rate >1.4) was recommended and hypertension
was well controlled by a strict prescription of dry weight,
without antihypertensive medication.
Data collection
From July 11, 2005 to July 26, 2006, each HDF treatment
was recorded in real time and compiled by a telemetry sys-BMC Nephrology 2008, 9:15 http://www.biomedcentral.com/1471-2369/9/15
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tem for dialysis units (Finesse, iSyMed, Butzback, Ger-
many), which provides exportable data to excel software.
Multiple information of each treatment was reported and
recorded in a database with an algorithm at intervals of 10
minutes. In each session we obtained an average of effec-
tive extracorporeal blood flow rate (Qb = mL/min),
dynamic arterial line pressure (DALP = mmHg), ionic
clearance (IK = mL/min) and access recirculation fraction
(%). Dialysis time was not taken into account in the final
analysis because the time of dialysis is Variable in each
patient. Significant residual renal function needing less
dialysis, patients request for earlier termination of the ses-
sion, nurses' decisions, blood clotting, etc.
Data analysis
Analysis was performed with a scatter plot. The X axis rep-
resented DALP, and Y axis Qb. We divided Qb in high
blood flow (> 400 ml/min), middle (300–399 ml/min)
and low flow (<300 ml/min). DALP was split in middle
arterial line pressure (-249 to -200 mmHg) and low arte-
rial line pressure (<-200 mmHg). For analysis purposes
we did not included treatments with high DALP (-300 to
-250 mmHg). Within these parameters, 6 prescription
quadrants were identified: A zone: Qb > 400 ml/min,
DALP -250 to -200 mmHg; B zone: Qb > 400 ml/min,
DALP -199 to-100 mmHg; C zone: Qb 300–399 ml/min,
DALP -250 to -200 mmHg; D zone: Qb 300–399 ml/min,
DALP -199 to -100 mmHg and E zone: Qb < 300 ml/min,
DALP -250 to -200 mmHg and F Zone: Qb < 300 ml/min,
DALP -199 to -100 mmHg. We compared staff prescrip-
tion adherence, ionic clearance and recirculation fraction
between the two groups of study. Additionally we com-
pared ionic clearance between zones in Group 2.
Statistical analysis
Parametric data distribution was expressed as mean and
standard deviation, and non parametric as median and
Inter Quartile Rank (IQR) 25–75. Test for Normality was
performed with Shapiro-Wilk test. Statistical analysis was
evaluated by T test, ANOVA and Wilcoxon's signed rank
test according to normality and grouping. P values of ≤
0.05 were considered statistically significant. SPSS for
Windows 13.0 software (SSPS, Inc., Chicago, IL) was used
for all statistical analysis.
Results
There were 91 patients, 72 in Group 1 with vascular access by
means of jugular catheter and 19 in Group 2 with AV fistulae.
35 females in Group 1, and 9 in Group 2. Mean age in Group
1 was 33.4 ± 15 vs 44.5 ± 16 in Group 2. There was no evi-
dence of cardiac dysfunction with ejection fraction of 58.6 ±
9.6% in Group 1 vs. 59.3 ± 4.8% (p = 0.68) in Group 2, by
the Simpson method of Echocardiography.
Previous to kidney transplantation, all patients in Group
1 were waiting for living donors (100%) and in Group 2
for cadaveric donors. No antihypertensive drugs were
used, intravenous iron was administered in 38 patients (4
in Group 2), erythropoietin was required in 6 patients (1
in Group 2) and 2 patients in Group 2 received vitamin D
analogues. We did not have vascular access failure in
Group 2 during the trial time.
We recorded 1877 treatments in Group 1 (20 treatments/
patient) and 1868 treatments in Group 2 (98 treatments/
patient). The distribution of treatments according to the
identified zone were as follows; in Group 1: A zone 695
(37%), B zone 150 (8%), C zone 604 (32.2%), D zone
272 (14.5%), E zone 77 (4.1%) and F zone 79 (4.2%) (P
< 0.000001), in Group 2: A zone 704 (37.7%), B zone 458
(24.5%), C zone 390 (21.0%), D zone 247 (13.2%), E
zone 19 (1%) and F zone 50 (2.6%) (P  < 0.000001).
Comparisons between both groups are represented in
table 1. 103 measures with DALP < -250 mmHg were
recorded in group 1 and 57 in group 2.
Staff adherence to Qb and DALP prescription in A, B, C
and D zones in Group 1 was 1526 treatments 81.3%,
while in Group 2 was 1571 treatments 84.1% (P = 0.02).
Dialysis time in Group 1 was different in each zone with
a range from 217 ± 26 minutes in E zone to 229 ± 25 min-
utes in D zone. Qb in Group 1, A zone was 448 ± 35 ml/
min vs. 360 ± 26 mL/min (P < 0.000001) in C zone. Qb
Anova between zones in Group 1 was P  < 0.000001.
(Table 2). DALP in Group 1 was similar in zone A, C and
E (P: NS). A zone vs B, D and F zones (P < 0.000001).
Dialysis time in Group 2 was different in each zone with
a range from 224 ± 24 minutes in F zone to 234 ± 20 min-
utes in C zone. Qb in Group 2 A zone was 442 ± 32 ml/
min vs. 369 ± 24 mL/min in C zone (P < 0.000001). Qb
Anova between zones in Group 2 was P  < 0.000001.
(Table 3). Dynamic arterial line pressure in Group 2 was
similar in zone A, C and E (P: NS), while there was a sig-
Table 1: Treatments distribution between zones, for catheters 
(group 1) and AV fistulae (group 2)
Zones Group 1
n
%G r o u p  2
N
% P-value
A zone 695 37.0 704 37.7 0.70
B zone 150 8.0 458 24.5 <0.0001
C zone 604 32.2 390 21.0 <0.0001
D zone 272 14.5 247 13.2 0.28
E zone 77 4.1 19 1.0 <0.0001
F zone 79 4.2 50 2.6 0.01
Total 1877 100 1868 100
A to F zones correspond to treatments distribution in Figure 1 and 
Figure 2, n, number of treatments; %, percentage of treatments.BMC Nephrology 2008, 9:15 http://www.biomedcentral.com/1471-2369/9/15
Page 4 of 8
(page number not for citation purposes)
nificant difference in A zone vs B, D and F zones (P <
0.000001).
Recirculation fraction in A zone was 10.0% (IQR 6.5 –
14.2) in Group 1 vs. 9.8% (IQR 7.5 – 14.1) in Group 2 (P
= 0.62). (Table 4). Recirculation in F zone was 14.5 (IQR
5.7 – 17.5) in Group 1 vs. 12.5 (IQR 7.5 – 19.2) in Group
2 (P = 0.83).
Ionic clearance in Group 1 was different in each zone in a
range from 214 ± 34 mL/min in A zone to 157 ± 34 mL/
min in F zone. Comparison of ionic clearance in A zone vs
B zone (216 ± 39 mL/min) was no significant, but when
comparing C zone (190 ± 33 mL/min) and D zone (189 ±
33 mL/min) to A, B, E and F zones was significant P <
0.000001 (Figure 1, Table 5).
Ionic clearance in Group 2 was different in each zone in a
range from 213 ± 35 mL/min in A zone to 169 ± 34 mL/
min in F zone. Anova between zones in Group 2 ionic
clearance was P < 0.000001 when comparing A zone vs C
(190 ± 33 mL/min) and A vs D (189 ± 34 mL/min) zones
(Figure 2, Table 5). Ionic clearance in A zone vs B zone
(210 ± 37 mL/min) was not statistically significant.
T test for ionic clearance performed in the same treatment
zones comparing Group 1 versus Group 2 was no signifi-
cant, with the exception of E zone, where greater ionic
clearance was found in Group 2 compared to Group 1
(182 ± 38 mL/min vs, 150 ± 36 mL/min respectively P =
0.001). There was no difference in ionic clearances
between zones that corresponded to an equivalent Qb,
such as A and B; C and D; and E an F (P = NS), in Grup1
as well as in Group 2 (Table 5).
Discussion
Dynamic arterial line pressure is a negative pressure gen-
erated by the machine's peristaltic pump. The dynamic
nomination must be, so that it translates the negative
pressure of the pump in movement from arterial line to
vascular access. This study describes extracorporeal blood
flow prescription based on DALP which permits to opti-
mize Qb until limits near to 500 ml/min could be
attained. The best extracorporeal blood flow (>400 ml/
min) (A and B zones) was achieved in higher percentage
in patients with AV fistulae accesses 62.2%, compared to
45% in the catheter group. On the other hand the lower
or worse extracorporeal blood flow in zones E and F
(<300 mL/min) was found in higher percentage in the
catheter group 8.3%, while in the fistulae group was 3.6%.
This is evidence that a better extracorporeal blow flow
from what it is currently recommended could be obtained
with AV internal fistulae. Contrary to what is usually
expected at higher blood flows, the recirculation fraction
was not modified in any zone, this means that the nega-
tive pressure in the arterial line between -200 to -250
mmHg did not affect the recirculation fraction, and even
though we did not measure access blood flow, the
unchanged recirculation fraction could be due to well
constructed vascular accesses. Dynamic arterial line pres-
sure had an average of -222 mmHg in A, C and D zones
(Group 1 and Group2) with the best extracorporeal blood
Table 2: Characteristics of time, Qb and DALP in catheters (group 1)
A zone B zone C zone D zone E zone F zone P-value
Time
(min)
220 ± 24 228 ± 25 223 ± 25 229 ± 25 217 ± 26 223 ± 28 <0.000001
Qb
(ml/min)
448 ± 35* 448 ± 36 360 ± 26* 350 ± 27* 276 ± 20 264 ± 28 <0.000001
DALP
(mmHg)
-224 ± 13** -180 ± 22** -223 ± 14 -181 ± 20** -222 ± 13 -167 ± 23** <0.000001
Time: length of treatment; Qb, extracorporeal blood flow; DALP dynamic arterial line pressure; A to F zones correspond to treatment distribution 
in Figures 1 and 2; *P > 0.000001 Qb between, A vs C and A vs D zones; **P < 0.000001 DALP A vs B and D zones and F zones.
Table 3: Characteristics of time, Qb and DALP in AV fistulae (group 2)
A zone B zone C zone D zone E zone F zone P-value
Time
(min)
232 ± 19 231 ± 20 234 ± 20 230 ± 22 227 ± 18 224 ± 24 0.007
Qb
(Ml/min)
442 ± 32* 452 ± 32 369 ± 24* *361 ± 29 283 ± 12 270 ± 34 <0.000001
DALP
(mmHg)
-221 ± 13** -174 ± 24** -224 ± 13 -167 ± 30** -220 ± 13 -143 ± 40** <0.000001
Time, length of treatment; Qb, extracorporeal blood flow; DALP, dynamic arterial line pressure; *P < 0.000001, Qb A vs. C and A vs. D zone; **P 
< 0.000001; DALP, A vs. B, D and F zones; P: NS, not significant, DALP A vs. C and E zonesBMC Nephrology 2008, 9:15 http://www.biomedcentral.com/1471-2369/9/15
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flow in each zone. DALP parameters could be used to for-
mulate diagnosis of access quality and help to monitor
extracorporeal blood flow over time (intradialysis and
interdialysis) (See figure 3). Therefore DALP parameters
could be helpful identifying catheter and AV fistulae dys-
function. Vascular access dysfunction which is defined
when an extracorporeal blood flow is below 300 mL/min
at a pre pump pressure of -220 mmHg, taken with Qb cut
point 300 mL/min as low extracorporeal blood flow
based on K/DOQI recommendation3. A zone with the
major blood flow and an optimal DALP would be the
aimed zone in each treatment. B zone is a special zone,
where the excellent quality of the access apparently does
not require prescription based on DALP. C zone is a mid-
dle flow zone that nevertheless has an optimized prescrip-
tion. Zone D is a zone that needs to be optimized, where
Table 4: Access recirculation for catheter (group 1) and AV fistulae (group 2)
Zones Group 1
Recirculation (%)
IQR Group 2
Recirculation (%)
IQR P-value
A zone 10.0 6.5 – 14.2 9.8 7.5 – 14.1 0.62
B zone 9.6 6.1 – 15.5 12.2 8.5 – 14.4 0.07
C zone 12.6 8.2 – 17.9 10.7 7.6 – 16.5 0.21
D zone 9.3 6.2 – 15.0 10.0 7.5 – 12.6 0.69
E zone 10.9 6.4 – 26.0 6.6 6.5 – 6.6 0.77
F zone 14.5 5.7 – 17.5 12.5 7.5 – 19.2 0.83
Recirculation: Access recirculation fraction; IQR, Interquartile range. A to F zones correspond to treatment distribution in Figures 1 and 2.
Scatter-plot and prescription zones in catheters (group 1) Figure 1
Scatter-plot and prescription zones in catheters (group 1). Scatter-plot and prescription zones in Group 1: Y Axis 
Extracorporeal blood flow (Qb) (mL/min). X axis Dynamic Arterial Line Pressure (DALP) (mmHg). A Zone: Qb > 400 ml/min, 
DALP -250 to -200 mmHg; B Zone: Qb > 400 ml/min, DALP-199 to -100 mmHg; C Zone: Qb 300–399 ml/min, DALP -250 to 
-200 mmHg; D zone: Qb 300–399 ml/min, DALP-199 to -100 mmHg; E Zone: Qb < 300 ml/min, DALP -250 to -200 mmHg; F 
Zone: QS < 300 ml/min, DALP -199 to -100 mmHg. Ionic clearance value is shown in each zone (mL/min) with arrows.BMC Nephrology 2008, 9:15 http://www.biomedcentral.com/1471-2369/9/15
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greater emphasis in obtaining an increase in the extracor-
poreal flow can be placed. Probably with an increase of
DALP this treatment zone and/or most of the treatments
would be located in A zone. D zone in higher percentage
was identified as the zone where staff failure to prescrip-
tion attachment occurred. E zone consisted of accesses
with low blood flow even though DALP was optimal.
Nevertheless with an optimized prescription E zone in AV
fistulas could correspond to immature accesses. F zone
consisted of accesses of poor quality superposed to a non-
optimal treatment prescription, probably if we optimize
DALP we could attain a prescription reaching C zone.
Ionic clearance in zones that corresponded to an equiva-
lent extracorporeal blood flow was no different, however
it is interesting to note that as mentioned previously the
procedures located in D zone, with ionic clearances of 189
± 34 could be improved with a better prescription of
DALP. The enhanced prescription could explain the
Table 5: Ionic clearance in catheter and AV fistulae
A zone B zone C zone D zone E zone F zone **P-value
Group 1 214 ± 34 216 ± 39 190 ± 33 189 ± 33 150 ± 36 157 ± 34 <0.000001
Group 2 213 ± 35* 210 ± 37 190 ± 36 189 ± 34* 182 ± 38 169 ± 34 <0.000001
*P-value 0.6 0.65 0.9 0.44 0.001 0.48
Group 1, Ionic clearance (mL/min) in catheters; Group 2, Ionic clearance in AV Fistulas; *P < 0.001 T test; **P < 0.0001; Anova test; A to F zones 
correspond to treatment distribution in Figures 1 and 2.
Scatter-plot and prescription zones in AV fistulae (group 2) Figure 2
Scatter-plot and prescription zones in AV fistulae (group 2). Scatter-plot and prescription zones in Group 2. Y Axis 
Extracorporeal blood flow (Qb) (mL/min). X axis Dynamic Arterial Line Pressure (DALP) (mmHg). A Zone: Qb > 400 ml/min, 
DALP -250 to -200 mmHg; B Zone: Qb > 400 ml/min, DALP-199 to -100 mmHg; C Zone: Qb 300–399 ml/min, DALP -250 to 
-200 mmHg; D zone: Qb 300–399 ml/min, DALP-199 to -100 mmHg; E Zone: Qb < 300 ml/min, DALP -250 to -200 mmHg; F 
Zone: QS < 300 ml/min, DALP -199 to -100 mmHg. Ionic clearance is shown in each zone (mL/min) with arrows. Ionic clear-
ance value is shown in each zone (mL/min) with arrows.BMC Nephrology 2008, 9:15 http://www.biomedcentral.com/1471-2369/9/15
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higher ionic clearance of 214+34 mL/min observed in A
zone.
Overall, the proposed policy to evaluate DALP and to aim
for maximum Qb is well established in most HD units
with properly trained nursing staff. The main problem is
when these targets (high Qb with acceptably low DALP)
can not be achieved.
As there was no statistical significance found in clearance
between A and B categories both in group 1 and group 2,
the final recommendation for using QB in excess of 400
ml/min should not say that those QBs should be
attempted only when DALP does not exceed -200 mmHg.
Otherwise, we are just providing confirmatory data that
dialysis catheters are not as good as a native A-V fistula for
the average patient in the short or long run after catheter
insertion. QB should in some way correspond to the dia-
lyser size chosen. High QB would be of no effect in a low
surface area dialysers and vice versa low QB would cause
coagulation problems in large area dialyser types.
Disadvantages of our study were non-measured access
blood flow and no available information on pain evalua-
tion during needle insertion. We do not have kt/v with
three samples, nevertheless, ionic dialysance and urea
clearance proved to be closely correlated (r2 = 0.89) [16].
Another disadvantage is we do not measure LDH and free
hemoglobin in patients at high pressures lower than -250
mmHg to diagnose hemolysis.
Our study describes a novel concept of optimizing dialysis
treatment prescription based on DALP identified zones,
that could be used in the future for a feedback system on
extracorporeal blood flow, by increasing or diminishing
intradialysis Qb guided by DALP (See figure 3).
Conclusion
In conclusion this investigation has shown that Qb pre-
scription can be optimized by DALP. DALP of -200
mmHg is recommended for obtaining the best Qb. Staff
adherence to DLAP treatment prescription could be
reached up to 81.3% in catheters and 84.1% in AV fistu-
lae.
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